Skip to main content

Empliciti FDA Approval History

FDA Approved: Yes (First approved November 30, 2015)
Brand name: Empliciti
Generic name: elotuzumab
Dosage form: Injection
Company: Bristol-Myers Squibb Company and AbbVie
Treatment for: Multiple Myeloma

Empliciti (elotuzumab) is a Signaling Lymphocyte Activation Molecule (SLAMF7)-directed immunostimulatory antibody indicated for the combination treatment of patients with multiple myeloma.

Development timeline for Empliciti

DateArticle
Nov  6, 2018Approval FDA Approves Empliciti (elotuzumab) Plus Pomalidomide and Dexamethasone, a New Immunotherapy Combination for Certain Patients with Relapsed or Refractory Multiple Myeloma
Nov 30, 2015Approval FDA Approves Empliciti (elotuzumab) for Multiple Myeloma
Sep  1, 2015FDA Accepts for Priority Review the BLA for Empliciti (elotuzumab) for the Treatment of Multiple Myeloma

See also

Empliciti (elotuzumab) Consumer information

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer